Boston Scientific Completes Enrollment in EVOLVE Clinical Trial
News Jan 25, 2011
The randomized, single-blind, non-inferiority trial will compare the SYNERGY Stent to the PROMUS Element™ Everolimus-Eluting Coronary Stent in patients with a single de novo native coronary artery lesion. The trial enrolled 291 patients at 29 sites in Europe, Australia and New Zealand, and completed enrollment four months ahead of schedule.
The SYNERGY Stent uses a bioabsorbable PLGA polymer and everolimus drug combination to create a thin, uniform coating confined to the outer surface of the stent. Once the drug has been delivered, the bioabsorbable coating resorbs in three to six months, leaving behind only a bare-metal stent. This technology is designed to provide the same degree of restenosis reduction as a conventional drug-eluting stent while offering faster and more complete vessel healing after stent implantation, which could potentially reduce the duration of required adjunctive medical therapies. The SYNERGY Stent features the same proprietary platinum chromium alloy and innovative stent design used in the PROMUS Element Stent to enable thinner struts, increased flexibility and a lower profile while reducing recoil and improving radial strength and visibility.
"We are pleased to complete the enrollment phase of the EVOLVE clinical trial well ahead of schedule," said Professor Ian Meredith, M.B.B.S., Ph.D., Director of MonashHeart, Monash Medical Centre, Melbourne, Australia, and Principal Investigator of the trial. "The brisk pace of enrollment reflects the strong interest in this innovative drug-eluting stent technology that could play an important role in helping reduce adverse events including late stent thrombosis."
"The SYNERGY Stent is designed to combine the acute performance advantages of the platinum chromium PROMUS Element Stent with an innovative bioabsorbable drug-polymer combination," said Keith D. Dawkins, M.D., Senior Vice President and Chief Medical Officer of Boston Scientific's Cardiology, Rhythm and Vascular Group. "We believe this technology will represent a significant advance for drug-eluting stents by reducing the amount of polymer and drug to which the vessel wall is exposed, while eliminating the coating on the inner surface of the stent where endothelial cell growth is required for healing."
The EVOLVE trial compares two doses of everolimus on the SYNERGY Stent (a PROMUS Element equivalent dose and a dose half that amount) randomized against a commercially available PROMUS Element Stent. The primary clinical endpoint is target lesion failure at 30 days, a composite measure of cardiac death, myocardial infarction and target lesion revascularization. The primary angiographic endpoint is in-stent late loss at six months as measured by quantitative coronary angiography (QCA). Patients will also be assessed by intravascular ultrasound (IVUS) at the time of initial procedure and at six months. Data from the trial will be used to support CE Mark approval for the SYNERGY Stent.
"Completion of enrollment brings our fourth-generation drug-eluting stent platform another step closer to commercialization," said Hank Kucheman, Executive Vice President and President of Boston Scientific's Cardiology, Rhythm and Vascular Group. "The SYNERGY Stent demonstrates our commitment to innovation and clinical science in pursuit of the most advanced treatment options for our physicians and their patients. We are confident that the SYNERGY Stent will enhance our leading drug-eluting stent portfolio."
A large clinical trial to assess treatments for preventing people at high risk from developing multidrug-resistant tuberculosis (MDR-TB) has begun. The study is comparing the safety and efficacy of a new MDR-TB drug, delamanid, with the decades-old TB drug isoniazid for preventing active MDR-TB disease in children, adolescents and adults at high risk who are exposed to adult household members with MDR-TB.READ MORE
An investigational drug for the treatment of sickle cell disease shows early promise in Phase 2a clinical trial. The orally administered drug, given to adult patients with sickle cell disease, is demonstrating tolerability and the ability to impact both red and white blood cell biomarkers of the disease.READ MORE